Chinese Neusoft Medical System's 16 Multi-Slice CT Receives FDA Authentication
This article was originally published in PharmAsia News
Executive Summary
Neusoft Medical System has received FDA authentication for its NeuViz 16 multi-slice spiral computed tomography scanner, with the first machinebound for the U.S. This marks the firm's second breakthrough in the global high-end medical device market after launching its positron emission tomography product this May (PharmAsia News, June 8, 2009). NeuViz, developed jointly with Philips, integrates technologies from both companies. Neusoft Medical officials ascribe the year's achievements to its continuous input in new technology and products. Besides the CT devices, the company will progressively launch a superconducting MRI, a linear accelerator and a PET/CT in the near future. (Click here for more - Chinese Language)
You may also be interested in...
Neusoft Medical System’s PET Obtains U.S. FDA Authentication
Neusoft Medical System, a subsidiary of Neusoft Group, has received the go-ahead from U.S. FDA to market its positron emission computer tomography technology in the U.S. It represents China's first corporation capable of producing PET technology and marketing it globally. At present, China spends hundreds of million dollars each year importing medical equipment. About 70 percent of the local high-end medical device market is monopolized by MNCs; for instance, GE, Siemens and Philips have cornered the CT and MR sector. Neusoft Medical System's PET technology not only fills a gap in the country's high-end medical equipment manufacturing, but also marks a milestone in reforming the trade structure of the healthcare industry. The company will sell its first machine to the U.S. this July. (Click here for more - Chinese Language)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.